LANSING, Mich., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig" or "The Company") announces an advance conference call advisory for all shareholders and other interested parties.
The Company plans to host a conference call for the purpose of discussing production, commercialization and scientific milestones as well as other corporate developments, featuring the Kraig's founder and CEO, Kim Thompson and is tentatively scheduled for late-March to mid-April, pending the travel schedule of Thompson and members of the scientific team.
Kraig recently announced that it signed a memorandum of understanding with SSM Industries Inc. (www.Ssmind.com) to jointly commercialize Kraig's Monster Silk(TM) recombinant spider silk. Other recent announcements included that the Company launched and is accelerating its Monster Silk(TM) pilot production program, as well as that it succeeded in creating "Big Red", a new type of recombinant spider silk.
The Company plans on releasing definitive details, including call-in details, time and format, at least one week prior to conference call and shareholders are invited to submit questions to firstname.lastname@example.org.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 email@example.comSource:Kraig Biocraft Laboratories, Inc